<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259363</url>
  </required_header>
  <id_info>
    <org_study_id>L_8330</org_study_id>
    <nct_id>NCT00259363</nct_id>
  </id_info>
  <brief_title>Oxaliplatin in Rectal Cancer</brief_title>
  <official_title>Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      -  Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed
           doses of oxaliplatin in this study

        -  Phase II: To determine the treatment efficacy according to response rates from phase I.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study cancelled because recruitment rate was too slow
  </why_stopped>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I : Maximum Tolerated Dose &amp; Recommended Dose</measure>
    <time_frame>Days 1, 15, 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II : Response and resectability rate.</measure>
    <time_frame>6 cycles in 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Rectal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The following information on clinical trials is provided for information purposes only to
        allow patients and physicians to have an initial discussion about the trial. This
        information is not intended to be complete information about the trial, to contain all
        considerations that may be relevant to potential participation in the trial, or to replace
        the advice of a personal physician or health professional.

        Main criteria are listed hereafter:

        Inclusion Criteria:

          -  ECOG: 0-2

          -  Histological proved rectal adenocarcinoma

          -  No chemotherapy treatment on the previous 6 months before inclusion.

          -  No previous pelvic radiotherapy treatment

        Exclusion Criteria:

          -  Important Biological abnormality (renal, hepatic and/or hematological)

          -  Intestinal occlusion or subocclusion

          -  Peripheral neuropathy

          -  Pregnant or breast-feeding women. Potential child-bearing women with a positive
             pregnancy test.

          -  Participation in other trials on the previous 4 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Mª Taboada</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

